Cargando…
Time for a lead-time definition? Author response to ‘Why the length of recurrence free survival or “lead-times” can be misleading. Comment on: Callesen LB, Takacova T, Hamfjord J, et al. Circulating DNA in patients undergoing loco-regional treatment of colorectal cancer metastases: a systematic review and meta-analysis’
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
SAGE Publications
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10026177/ https://www.ncbi.nlm.nih.gov/pubmed/36950273 http://dx.doi.org/10.1177/17588359231156393 |
| _version_ | 1784909490323193856 |
|---|---|
| author | Spindler, Karen-Lise Garm Callesen, Louise Bach Arnold, Dirk |
| author_facet | Spindler, Karen-Lise Garm Callesen, Louise Bach Arnold, Dirk |
| author_sort | Spindler, Karen-Lise Garm |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10026177 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | SAGE Publications |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-100261772023-03-21 Time for a lead-time definition? Author response to ‘Why the length of recurrence free survival or “lead-times” can be misleading. Comment on: Callesen LB, Takacova T, Hamfjord J, et al. Circulating DNA in patients undergoing loco-regional treatment of colorectal cancer metastases: a systematic review and meta-analysis’ Spindler, Karen-Lise Garm Callesen, Louise Bach Arnold, Dirk Ther Adv Med Oncol Letter to the Editor SAGE Publications 2023-03-17 /pmc/articles/PMC10026177/ /pubmed/36950273 http://dx.doi.org/10.1177/17588359231156393 Text en © The Author(s), 2023 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
| spellingShingle | Letter to the Editor Spindler, Karen-Lise Garm Callesen, Louise Bach Arnold, Dirk Time for a lead-time definition? Author response to ‘Why the length of recurrence free survival or “lead-times” can be misleading. Comment on: Callesen LB, Takacova T, Hamfjord J, et al. Circulating DNA in patients undergoing loco-regional treatment of colorectal cancer metastases: a systematic review and meta-analysis’ |
| title | Time for a lead-time definition? Author response to ‘Why the length
of recurrence free survival or “lead-times” can be misleading. Comment on:
Callesen LB, Takacova T, Hamfjord J, et al. Circulating DNA in patients
undergoing loco-regional treatment of colorectal cancer metastases: a systematic
review and meta-analysis’ |
| title_full | Time for a lead-time definition? Author response to ‘Why the length
of recurrence free survival or “lead-times” can be misleading. Comment on:
Callesen LB, Takacova T, Hamfjord J, et al. Circulating DNA in patients
undergoing loco-regional treatment of colorectal cancer metastases: a systematic
review and meta-analysis’ |
| title_fullStr | Time for a lead-time definition? Author response to ‘Why the length
of recurrence free survival or “lead-times” can be misleading. Comment on:
Callesen LB, Takacova T, Hamfjord J, et al. Circulating DNA in patients
undergoing loco-regional treatment of colorectal cancer metastases: a systematic
review and meta-analysis’ |
| title_full_unstemmed | Time for a lead-time definition? Author response to ‘Why the length
of recurrence free survival or “lead-times” can be misleading. Comment on:
Callesen LB, Takacova T, Hamfjord J, et al. Circulating DNA in patients
undergoing loco-regional treatment of colorectal cancer metastases: a systematic
review and meta-analysis’ |
| title_short | Time for a lead-time definition? Author response to ‘Why the length
of recurrence free survival or “lead-times” can be misleading. Comment on:
Callesen LB, Takacova T, Hamfjord J, et al. Circulating DNA in patients
undergoing loco-regional treatment of colorectal cancer metastases: a systematic
review and meta-analysis’ |
| title_sort | time for a lead-time definition? author response to ‘why the length
of recurrence free survival or “lead-times” can be misleading. comment on:
callesen lb, takacova t, hamfjord j, et al. circulating dna in patients
undergoing loco-regional treatment of colorectal cancer metastases: a systematic
review and meta-analysis’ |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10026177/ https://www.ncbi.nlm.nih.gov/pubmed/36950273 http://dx.doi.org/10.1177/17588359231156393 |
| work_keys_str_mv | AT spindlerkarenlisegarm timeforaleadtimedefinitionauthorresponsetowhythelengthofrecurrencefreesurvivalorleadtimescanbemisleadingcommentoncallesenlbtakacovathamfjordjetalcirculatingdnainpatientsundergoinglocoregionaltreatmentofcolorectalcancermetastasesasystematicreviewandmetaana AT callesenlouisebach timeforaleadtimedefinitionauthorresponsetowhythelengthofrecurrencefreesurvivalorleadtimescanbemisleadingcommentoncallesenlbtakacovathamfjordjetalcirculatingdnainpatientsundergoinglocoregionaltreatmentofcolorectalcancermetastasesasystematicreviewandmetaana AT arnolddirk timeforaleadtimedefinitionauthorresponsetowhythelengthofrecurrencefreesurvivalorleadtimescanbemisleadingcommentoncallesenlbtakacovathamfjordjetalcirculatingdnainpatientsundergoinglocoregionaltreatmentofcolorectalcancermetastasesasystematicreviewandmetaana |